文献速递中医内科中药与中成药合理使用

加减麻子仁丸治疗姑息性癌症患者便秘的随机安慰剂对照预试验

A pilot randomized placebo-controlled study on modified MaZiRenWan: a formulated Chinese medicine to relieve constipation for palliative cancer patients.
PubMed 文献 · Chin Med · 2022-03-02

结果显示,麻子仁丸组全局改善率为59.3%(16/27),高于安慰剂组的28.6%(8/28),P=0.022;麻子仁丸组排便频率增加,便秘严重程度和排便费力减轻(P<0.05),未报告与研究药物相关的严重不良事件。

要点

  • 加减麻子仁丸可改善晚期癌症便秘患者的全局评估。
  • 麻子仁丸组排便频率增加,便秘严重程度和排便费力减轻。
  • 预试验未报告与研究药物相关的严重不良事件。

核心结论

  • 加减麻子仁丸耐受性良好,可缓解晚期癌症患者便秘,可作为姑息治疗中便秘的潜在治疗选择。

研究设计与样本

  • 排除标准包括认知障碍、结肠造口或胃肠道梗阻、预计生存期小于一个月。
  • 允许根据患者中医证型对麻子仁丸进行个体化加减。

主要发现

  • 麻子仁丸组全局评估改善率为59.3%(16/27),安慰剂组为28.6%(8/28),P=0.022。
  • 麻子仁丸组排便频率显著增加,便秘严重程度和排便费力显著减轻(P<0.05)。
  • 未报告因研究药物导致的严重不良事件。

关键数值与推荐

  • 主要结局为全局改善评估,反映便秘改善、不变或恶化。
  • 麻子仁丸组全局评估改善率59.3%(16/27),安慰剂组28.6%(8/28),P=0.022。
  • 麻子仁丸组排便频率增加、便秘严重程度和排便费力减轻,P<0.05。

临床怎么用

  • 对晚期癌症姑息治疗中便秘患者,可考虑在现有泻药治疗基础上加用加减麻子仁丸。
  • 可根据中医证型进行个体化加减。
  • 需关注患者认知状态、有无结肠造口或胃肠道梗阻及预计生存期。

局限性

  • 研究允许根据中医证型个体化加减麻子仁丸,可能影响组间同质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Constipation is a common problem among advanced cancer patients; however, many of them find limited effective from current therapies. Thus, we aimed to test the effect of a traditional Chinese herbal formula, modified MaZiRenWan (MZRW), by comparing with placebo among palliative cancer patients with constipation. METHODS: This is a randomized, double-blind, placebo-controlled trial. Participants aged over 18 were recruited and randomized to MZRW or placebo group in addition to current prescriptions (including ongoing laxatives treatment) for two weeks. Exclusion criteria included cognitive impairment, presence of a colostomy or gastrointestinal obstruction and estimated life expectancy of less than one month. Individualized modification of MZRW was allowed according to the traditional Chinese medicine (TCM) pattern of patient. The primary outcome was the global assessment of improvement, which reflected whether the constipation had improved, remained the same or worsened. RESULTS: Sixty patients, with mean age 75.2 years (range 47-95 years), were randomized to MZRW or placebo group. Among the MZRW group, 59.3% (16/27) had improvement in the global assessment score, as compared with 28.6% (8/28) of the placebo group (p-value = 0.022). Besides, the MZRW group had significant increase in stool frequency, and reduction in constipation severity and straining of defecation (p-value < 0.05). No serious adverse event was reported due to the research medication. CONCLUSION: This pilot trial suggests modified MZRW is well-tolerated and effective for relief of constipation in patients with advance cancer. It could be considered as a potential treatment option for constipation in palliative care. TRIAL REGISTRATION: The trial had been registered in ClinicalTrials.gov with identifier number NCT02795390 [ https://clinicaltrials.gov/ct2/show/NCT02795390 ] on June 10, 2016.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Cheng CW, Mok HF, Yau CWS, et al. A pilot randomized placebo-controlled study on modified MaZiRenWan: a formulated Chinese medicine to relieve constipation for palliative cancer patients. Chin Med. 2022. PMID: 35236375. doi:10.1186/s13020-022-00580-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。